Observational studyNeurosurgical review2023
Glucose-albumin ratio as new biomarker for predicting mortality after intracerebral hemorrhage.
Observational study in Neurosurgical review, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 10 citations in OpenAlex.
- Preoperative Glucose-to-Albumin Ratio as a Prognostic Marker for Survival in Pancreatic Cancer Patients Undergoing Pancreatectomy.Cancer medicine · 2026Article
- Preoperative Glucose-Albumin Ratio and Its Association with Postoperative Outcomes in Critically Ill Adult Burn Patients: A Retrospective Cohort Study of 1119 Patients.Diagnostics (Basel, Switzerland) · 2026Article
- Glucose-to-albumin ratio predicts short-term mortality in critically ill patients with acute pancreatitis.Scientific reports · 2026Article
- Predictive value of the monocyte-to-albumin ratio at admission for 30-day mortality in elderly patients with spontaneous intracerebral hemorrhage: a retrospective analysis.Frontiers in neurology · 2026Article
- Relationship between serum glucose-to-albumin ratio and kidney stones among nondiabetic U.S. adults: a population-based study.Translational andrology and urology · 2025Article
- Association between glucose-to-albumin ratio and ischemic stroke risk in patients with coronary heart disease: a machine learning-based predictive model analysis.BMC cardiovascular disorders · 2025Article
- A retrospective analysis of the correlation between the glucose-to-albumin ratio and 28-day mortality in sepsis patients.BMC infectious diseases · 2025Article
- Death risk prediction model for patients with non-traumatic intracerebral hemorrhage.BMC medical informatics and decision making · 2025Article
- Evaluation of novel glucose-related blood biomarkers for predicting in-hospital mortality in patients with acute ischemic stroke.PloS one · 2025Article
- Glucose-albumin ratio (GAR) as a novel biomarker for predicting postoperative pneumonia (POP) in older adults with hip fractures.Scientific reports · 2024Article
- Predictive Value of Fibrin Fibrinogen Degradation Products-to-Potassium Ratio for Poor Functional Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Case-Control Study.Neurocritical care · 2024Article
- Association between nonalcoholic fatty liver disease and increased glucose-to-albumin ratio in adults without diabetes.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to evaluate the prognostic value of blood-based biomarkers and their combinations, in particular the glucose-albumin ratio (GAR), in patients with spontaneous intracerebral hemorrhage (ICH).
methodsA retrospective observational study on 2481 patients from one hospital was conducted and validated with 602 patients from another. We assessed 15 biomarkers and focused on GAR to elucidate its prognostic and predictive value for outcomes in both cohorts. The primary outcome was mortality at 90 days.
resultsThe ratio of glucose-to-albumin, defined as GAR, was superior to other biomarkers for predicting mortality at 90 days in patients with ICH (AUC = 0.72). High GAR (using the best cutoff value of 0.19) was associated with increased mortality at 90 days (odds ratios of 1.90, 95% CI 1.54-2.34) and all-cause mortality in the first 3 years after admission (hazard ratio of 1.62, 95% CI 1.42-1.86). All aforementioned findings for GAR were successfully validated in an external independent cohort.
conclusionsGAR may be a valuable biomarker for predicting the mortality of patients with ICH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.